The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Moniman, I am totally with you. When Moulding decided to list the business, the listing came with rules and responsibilities, some written, many not.
If you join a "game" you know what you are getting yourself and your team into. You can't hope to join a game and then change the rules that have existed forever just to suit your mood.
There's no getting away from the fact Moulding has a very controlling personality, he is awfully vain for a guy over 30, he loves publicity but cannot handle criticism and none of those are positive traits in a CEO of a public company. I do think he and his team are running out of ideas. I buy shares to hold for up 2 and occasionally 3 years. I had a 12 month stance with THG and here I am 16 months later frustrated with myself with not cashing out around the Apollo bid. I reckon I will be holding a long while to see a decent payback unless Moulding goes.
There is nothing to be gained by comparing them. Obviously they are in different sectors.
THG have very little IP that is providing a genuine competitive advantage whereas Darktrace's whole business is based on home grown IP which differentiates their offering for others.
Respect OAC, I am happy Darktrace shareholder and there is simply no comparison between MM and Poppy. Poppy is a class act and has demonstrated how to navigate so much more negativity than Moulding has ever experienced.
I know he won't, but I sincerely wish Moulding would see sense and stand down but I cannot see a set of circumstances where he would
Really interesting link and thanks for posting it. My only comment is I cannot see THG spinning off Nutrition until its in much better shape because MM would want the very best price and he would want to be confident of its future because he simply could not handle the American financial community if they turned against THG and himself.
Based on this my instinct says it won't be separately listed until 2026 at the earliest.
Obviously I would be delighted to proved wrong.
Here's the thing, no matter how much the app usage has grown beauty saw good growth whilst nutrition declined so you can't yet see any evidence of the app usage changing the performance of the business and that's what counts
About as much use as good old Clinton :-)
https://youtu.be/Rd79Ie_vWyQ?si=fGuMA2yJJF1WSfcM
Another viewpoint might be that you would have to be something of a fool to take note of someone with a 2 post history, who calls people with a different opinion to thiers idiots, gobsh*yes and Muppets. 🙄
The only declared offer was £1.70 and a great many of us have questions about that offer.
Every other mention of any offer or bid has no attributable value, none, zero, zilch. So talk of £2, £3 or anything else is nonsense.